Erythromycin (Erycette)

A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.

Also Known As:

Networked: 3197 relevant articles (379 outcomes, 398 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Chapman, Marianne J: 6 articles (06/2012 - 07/2005)
2.	Ren, Weiping: 6 articles (08/2011 - 02/2006)
3.	Markel, David C: 5 articles (08/2014 - 07/2009)
4.	Kohno, Shigeru: 5 articles (01/2014 - 04/2003)
5.	Nguyen, Nam Q: 5 articles (10/2011 - 02/2007)
6.	Kenyon, S: 5 articles (10/2010 - 01/2001)
7.	Taylor, D J: 5 articles (10/2008 - 03/2001)
8.	Soriano, Francisco: 5 articles (11/2006 - 11/2003)
9.	Ponte, Carmen: 5 articles (11/2006 - 11/2003)
10.	Cenjor, Carlos: 5 articles (11/2006 - 11/2003)

Related Diseases

1.	Infection 06/01/1991 - "at 48 and 65 h after infection led to complete clearance of bacteria from the lungs and blood, whereas erythromycin-treated mice remained bacteremic. " 08/01/2001 - "Erythromycin has been shown to be beneficial for panbronchiolitis, a disorder linked to infection with Pseudomonas aeruginosa. " 04/01/1997 - "Erythromycin is generally effective in this infection, but its use, especially in children, is complicated by the need for multiple daily doses, a lengthy treatment period and a high rate of gastrointestinal side effects. " 12/24/2015 - "The antimicrobial activities of the conjugates were retained in vivo, with the H-TriA1-erythromycin conjugate proving a more effective treatment of Klebseilla pneumoniae infections in mice than erythromycin alone or in combination with H-TriA1. " 08/01/2001 - "Erythromycin is effective in control of ureaplasma urealyticum infection among pregnant women through cutting off vertical transmission passway and lowering adverse perinatal outcomes against ureaplasma urealyticum."
2.	Pneumonia (Pneumonitis) 07/01/1993 - "On the basis of these data, a rational initial therapeutic approach to community-acquired pneumonia, as well as to nosocomial pneumonia in certain circumstances, has to include an antimicrobial agent that is clinically effective against Legionella spp. Clinical studies have provided evidence that erythromycin is the first-line treatment. " 12/01/1997 - "Erythromycin therapy was effective against the pneumonia. " 06/01/1991 - "pneumoniae pneumonia relative to the efficacy of erythromycin." 01/01/2006 - "Pharmacokinetics of erythromycin after its intravenous and cell-associated administration in patients with community-acquired pneumonia and the clinical efficacy of the method were evaluated. " 05/01/1990 - "[Bacteremic pneumonia caused by Haemophilus influenzae cured with oral erythromycin]."
3.	Acne Vulgaris 08/01/2005 - "There is a gradual decrease in the efficacy of topical erythromycin in clinical trials of therapeutic intervention for acne, which is probably related to the development of antibiotic-resistant propionibacteria." 01/01/2012 - "Efficacy of intense pulsed light combined with topical erythromycin solution 2% versus topical erythromycin solution 2% alone in the treatment of persistent facial erythematous acne macules." 09/01/2001 - "All but two infants with moderate acne responded well to oral (paediatric) erythromycin 125 mg twice daily and topical therapy. " 05/01/1982 - "The efficacy of a topical preparation containing erythromycin in the treatment of acne." 08/01/2005 - "Analysis of clinical studies investigating the effect of topical erythromycin in acne patients indicates a significant decrease in the effect of this antibiotic on inflammatory and noninflammatory lesion count over time (r = -2.140, P = 0.001 and r = -2.032, P = 0.001, respectively). "
4.	Inflammation 11/01/1995 - "It has been established that long-term low-dose erythromycin therapy (EM therapy) is very effective for sinobronchial syndrome, a common condition in Japan characterized by chronic upper and lower airway inflammation. " 02/01/1999 - "Recent clinical studies have demonstrated the efficacy of erythromycin for treating patients with chronic lower respiratory tract inflammation. " 06/01/2012 - "Increasing evidence shows that erythromycin, which is a macrolide antibiotic, ameliorates chronic inflammation via mechanisms independent of its antibacterial activity. " 07/01/2000 - "Our conclusion provides an explanation for the clinical efficacy of erythromycin in neutrophil-mediated airway inflammation." 01/01/2011 - "The aim of this study was to explore a cyclodextrin-erythromycin (CD-EM) complex for sustained treatment of orthopedic inflammation. "
5.	Respiratory Tract Infections (Respiratory Tract Infection) 05/01/1989 - "This study indicates that both formulations of erythromycin are highly effective for routine, empirical treatment of acute respiratory tract infections. " 08/06/1983 - "The bactericidal and tissue-penetrating properties of this antibiotic are described and the suggestion that erythromycin has a very useful spectrum of activity in respiratory tract infections is supported by a variety of studies. " 01/01/1956 - "The efficacy of erythromycin in respiratory infections." 10/01/1954 - "Efficacy of erythromycin in the treatment of acute respiratory infections." 10/01/2001 - "pneumoniae and erythromycin-resistant Streptococcus pyogenes are available from clinical trials, this drug appears promising for respiratory infections caused by these pathogens."

Related Drugs and Biologics

1.	Clarithromycin (Biaxin)
2.	Azithromycin (Zithromax)
3.	Tetracycline (Achromycin)
4.	Anti-Bacterial Agents (Antibiotics)
5.	Penicillins (Penicillin)
6.	Rifampin (Rifampicin)
7.	Amoxicillin (Wymox)
8.	Clindamycin (Cleocin)
9.	Doxycycline (Vibramycin)
10.	Macrolides

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Enteral Nutrition (Feeding, Tube)
3.	Drug Therapy (Chemotherapy)
4.	Injections
5.	Chemoprevention